Results 191 to 200 of about 463,429 (352)

Tyrosine Kinase Inhibitor [PDF]

, 2020
openaire   +1 more source

Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia. [PDF]

Diagnostics (Basel)
Russo S, Fazio M, Mirabile G, Sciaccotta R, Stagno F, Allegra A.   +5 more
europepmc   +1 more source

FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus [PDF]

, 2020
LENA HUBER, Richard Birk, MANUEL KNUETTEL, Nicole Rotter, Christoph Aderhold, Claudia Scherl, Anne Lammert, Frederic Jungbauer, Benedikt Kramer   +8 more
openalex   +1 more source

Decoding Human Placental Cellular and Molecular Responses to Obesity and Fetal Growth

Advanced Science, EarlyView.
Women with obesity often deliver large‐for‐gestational‐age (LGA) infants. Single‐nucleus RNA sequencing of term placenta reveals that hypoxia and TNF‐α signaling in syncytiotrophoblasts are featured in maternal obesity, but inflammatory signatures in Hofbauer cells and response to lipid or carbohydrate metabolism in fibroblasts are specific to LGA.
Hong Jiang, Emilie Derisoud, Denise Parreira, Nayere Taebnia, Paulo R. Jannig, Reza Zandi Shafagh, Allan Zhao, Congru Li, Macarena Ortiz, Manuel Alejandro Maliqueo, Elisabet Stener‐Victorin, Volker M. Lauschke, Qiaolin Deng   +12 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors

, 2020
Chao Cheng, Yanding Zhao, Evelien Schaafsma, Yi‐Lan Weng, Christopher I. Amos   +4 more
openalex   +2 more sources

Wedelolactone, a Novel TLR2 Agonist, Promotes Neutrophil Differentiation and Ameliorates Neutropenia: A Multi‐Omics Approach to Unravel the Mechanism

Advanced Science, EarlyView.
Wedelolactone (WED), a natural TLR2 agonist, promotes neutrophil differentiation and enhances bactericidal function, offering a potential therapeutic strategy for neutropenia. Using a multi‐omics approach, this study reveals that WED activates the TLR2/MEK/ERK pathway, upregulating key transcription factors (PU.1, CEBPβ) to drive neutrophil development.
Long Wang, Zhichao Li, Tianci Hu, Qinyao Li, Linwei Zhang, Xinyue Mei, Xiao Qi, Sheng Liu, Weijie Kong, Jiesi Luo, Anguo Wu, Feihong Huang, Sirui Li, Shuang Dai, Chunxiang Zhang, Rong Li, Jianming Wu   +16 more
wiley   +1 more source

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. [PDF]

Oncol Rev
Santamaria F, Roberto M, Maltese G, Nicolella F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D.   +13 more
europepmc   +1 more source

Coexisting with Clonal Evolution and BCR-ABL Mutant in CML Patients Treated with Second-generation Tyrosine Kinase Inhibitors Predict the Discrepancy of in vitro Drug Sensitivity [PDF]

, 2010
Jae‐Sook Ahn, Yeo-Kyeoung Kim, Se Ryeon Lee, Yu Li, Deok‐Hwan Yang, Sang‐Hee Cho, Hyun Jeong Shim, Woo Kyun Bae, Je‐Jung Lee, Ik-Joo Chung, Myung Gun Shin, Hyeoung-Joon Kim   +11 more
openalex   +1 more source

HRS Degradation‐Induced Nicotinamide Deficiency in Placental Extracellular Vesicles Triggers Preeclampsia by Disrupting Maternal‐Fetal Immune Homeostasis

Advanced Science, EarlyView.
This study shows that lower NAM levels in PE‐derived pEVs correlate with disease severity. NAM‐deficient pEVs reduce Th1 and Th17 inhibition, leading to PE‐like symptoms. NAM in pEVs inhibits Th1 via SIRT1 and Th17 via macrophages. Reduced NAM in PE‐EVs is due to decreased HRS expression in trophoblasts, resulting from elevated HSP27.
Haiyi Fei, Yuhan Lin, Xiu Liu, Xiaohong Zhu, Xiaowen Lu, Zhan Shi, Fan Jia, Shiqian Xu, Ling Fang, Lingling Jiang, Songying Zhang   +10 more
wiley   +1 more source